Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Investing.com - H.C. Wainwright has maintained its Buy rating and $5.00 price target on Invivyd Inc. (NASDAQ:IVVD), currently trading at $1.28, following a management meeting at the firm’s 27th Annual Global Investment Conference on September 8. According to InvestingPro data, analyst consensus remains bullish with price targets ranging from $1 to $5.
The research firm highlighted FDA alignment on a single pivotal Phase 2/3 randomized, placebo-controlled prevention trial for VYD2311, Invivyd’s next-generation monoclonal antibody. The trial features a 12-week primary endpoint designed to mirror the Phase 3 CANOPY Cohort B and is intended to support a full biologics license application.
H.C. Wainwright noted VYD2311’s profile includes a 76-day observed half-life for intramuscular dosing, a favorable safety record across multiple administration routes, and an estimated 17-fold potency improvement over PEMGARDA (pemivibart) against dominant variants.
The firm’s analysis also mentioned a potential head-to-head safety evaluation versus vaccines, which could position VYD2311 as a scalable vaccine-like prophylaxis option.
Invivyd’s management team at the conference included CFO Bill Duke and SVP of Finance Katie Falzone, who participated in discussions about the company’s development pipeline and regulatory strategy.
In other recent news, Invivyd Inc. has completed a public offering, raising approximately $57.5 million in gross proceeds. The offering included 89,234,480 shares of common stock and pre-funded warrants, with the underwriter’s option fully exercised. Prior to this, the company had priced a $50 million public offering at $0.52 per share, managed by Cantor as the sole book-running manager. These financial moves aim to support Invivyd’s clinical programs. Additionally, H.C. Wainwright has maintained a Buy rating on Invivyd, citing a clear regulatory path for VYD2311, a next-generation monoclonal antibody for COVID-19. The FDA has agreed to a single Phase 2/3 trial for this antibody, which could form the basis for a Biologics License Application. This development comes amid increased attention on Invivyd as a potential alternative to traditional COVID-19 vaccines. The company recently gained momentum after securing a $58 million financing round backed by RA Capital and Janus Henderson.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.